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Ceramides are lipid metabolites implicated in the metabolic dysregulation that accompanies dyslipidaemia
and obesity. Using a genetic mousemodel to acutely degrade ceramides in adipose tissue or the liver (i.e., by
conditionally expressing acid ceramidase), in this issue of Cell Metabolism Xia et al. (2015) identify roles for
these molecules in insulin resistance, steatohepatitis, and interorgan communication.The accumulation of lipid metabolites in
tissues not suited for nutrient storage
gives rise to the panoply of defects that
underlie diabetes and cardiovascular dis-
ease. Of the lipids that accrue, sphingoli-
pids such as ceramides are particularly
deleterious. Interventional studies un-
equivocally demonstrate that inhibition
of sphingolipid biosynthesis ameliorates
insulin resistance, steatohepatitis, and
other metabolic disorders (Chavez and
Summers, 2012; Holland et al., 2007; Tur-
pin et al., 2014). In this issue of Cell Meta-
bolism, Xia et al. (Xia et al., 2015) identify
a new therapeutic strategy for lowering
ceramides and improving metabolic
health—driving ceramide degradation.
The study focuses on ceramidase, an
enzyme that removes an acyl-chain from
ceramide, converting it to sphingosine,
which does not oppose insulin signaling
or induce apoptosis (Chavez et al., 2005;
Lang et al., 2011). The impetus for this
study was the observation that the broad
spectrum of activities of the antidiabetic
and cardioprotective adiponectin could
be explained by its activation of a ceram-
idase, likely one intrinsic to its receptors
(Holland et al., 2011). Adiponectin recep-
tors bear sequence homology with ce-
ramidase enzymes, and substitution of
residues predicted to be important for ce-
ramidase activity renders them ineffec-
tual. Infusion of recombinant adiponectin
or transgenic overexpression of adipo-
nectin in mice increases ceramidase ac-
tivity and depletes ceramides in various
tissues. Moreover, genetic ablation of adi-
ponectin receptors exacerbates sphingo-
lipid-dependent toxicity. These findings
suggest that ceramide depletion could
be a unifying mechanism to explain the
pleiotropic actions of the adipokine.
Xia and colleagues investigated
whether acutely increasing ceramidaseactivity was sufficient to recapitulate
adiponectin action in liver and adipose
tissue. They generated transgenic mice
that express acid ceramidase (AC) driven
by tissue-specific, tetracycline response
elements, allowing for the selective and
acute deacylation of ceramides in either
the liver or adipose tissue. The authors
observed profound improvements in
hepatic steatosis, adipose morphology,
and glucose metabolism following
ceramidase expression in either locale
(Figure 1).
Doxycycline-inducible, liver-specific
ceramidase overexpressionwasachieved
by generatingmice expressing an albumin
promoter-driven Cre recombinase, a Cre-
dependent tetracycline-controlled trans-
activator, and a tetracycline-responsive
acid ceramidase (Alb-AC). In Alb-AC
mice fed a high-fat diet, doxycycline
increased insulin sensitivity owing to
improved insulin signaling and action in
both the liver (i.e., increased repression
of hepatic glucose output) and adipose
tissue (i.e., increased glucose uptake).
The regimen did not affect glucose
disposal in muscle. Transgene expression
also reduced liver triglycerides owing to
increased hepatic triglyceride export and
decreased fatty acid uptake.
Doxycycline-inducible, adipose-spe-
cific ceramidaseexpressionwasachieved
by crossing the Tet-responsive acid ce-
ramidase mice with ones harboring an
adiponectin-reverse tetracycline (Art)
transgene. Overexpression of ceramidase
in adipose tissue protected these Art-AC
mice from diet-induced insulin resistance,
again due to increased insulin action in
both adipose tissue and the liver. Adipose
tissue also displayed reduced adipose
inflammation and fibrosis.
These findings revealed the existence
of a novel crosstalk mechanism betweenCell Metabolism 2the liver and adipose tissue. The benefi-
cial metabolic effects were independent
of changes in body weight, and cerami-
dase expression was confined to the
intended tissue. The intervention selec-
tively targeted sphingolipids, as other
lipids implicated in insulin resistance
(e.g., diacylglycerol) were unaffected.
Thus, changes in the sphingolipidome in
one tissue affected the metabolic health
of the other.
Xia and colleagues also demonstrated
that acute ceramidase activation reversed
pre-existing steatosis and insulin resis-
tance. The rapidity with which adipose
ceramidase overexpression reversed
metabolic impairment was impressive,
occurring within 3 days. Expression of ce-
ramidase in the liver also resolved insulin
resistance and steatosis, but the effect
took considerably longer.
Several mechanisms have been
described to explain ceramide effects on
insulin sensitivity and liver steatosis.
Ceramides inhibit insulin signaling to Akt
through parallel pathways involving pro-
tein phosphatase 2A and protein kinase
C-z (PKCz) (Chavez and Summers,
2012). Certain ceramides (i.e., C16-ce-
ramides) also have been reported to
induce liver steatosis through the inhibi-
tion of oxidative phosphorylation (Raichur
et al., 2014; Turpin et al., 2014). Xia and
colleagues described a new role, with
ceramide inducing lipid uptake into the
liver, but not adipose tissue. Both Alb-
AC and Art-AC mice displayed doxycy-
cline-dependent increases in expression
of CD36, a protein required for fatty acid
uptake. PKCz again emerged as the crit-
ical intermediary. Exogenous ceramides
stimulated CD36 translocation to the
membrane and lipid uptake via a PKCz-
dependent mechanism. The pathway
appeared relevant in vivo, as injection2, August 4, 2015 ª2015 Elsevier Inc. 195
Figure 1. Schematic Depicting the Effect of Adipose and Liver
Ceramidase Activation on Metabolic Homeostasis
Xia and colleagues (Xia et al., 2015) studied new mouse models allowing for
the acute induction of acid ceramidase in liver and adipose tissue. Increasing
rates of ceramide deacylation in either location markedly improved the meta-
bolic health of both tissues, revealing new roles for sphingolipids in liver-fat
crosstalk.
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Previewswith a PKCz inhibitor rapidly
improved insulin sensitivity
and reduced hepatic lipid
accumulation.
The role of ceramides in he-
patic insulin resistance and
steatosis has been conten-
tious. Though numerous
studies reveal that interven-
tions which deplete ceram-
ides improve metabolic ho-
meostasis in mice (Chavez
and Summers, 2012; Holland
et al., 2007; Turpin et al.,
2014), correlational studies
investigating relationships
between ceramides, hepatic
steatosis, and insulin resis-
tance have been discordant
(Kumashiro et al., 2011; Yetu-
kuri et al., 2007). A major
concern with the correlational
studies is the challenge of
profiling sphingolipids thatdo not exist at steady-state concentra-
tions or which reside in distinct intracel-
lular pools. More complete temporal-
spatial profiling of the sphingolipidome
(e.g., in relation to feeding) could inform
this debate. Other important questions
also remain. The precise sensing mech-
anisms through which very small
changes in ceramides modulate PKCz
or other nutrient sensors are unresolved.
Moreover, the nature of the signal
between adipose tissue and the liver
is unclear. One possibility is that circu-
lating sphingolipids themselves are the
signaling entities. Determination of the196 Cell Metabolism 22, August 4, 2015 ª201tissue of origin of the impactful lipids
has significant therapeutic implications.
Is adipose a source for ceramides or a
sink where they are removed from the
circulation?
In summary, the development of an
acute, genetic means to modulate cer-
amide levels in adult mouse tissues re-
veals new insight into our understanding
of the regulatory mechanisms linking
nutrient sensing to metabolic regulation.
Enzymes controlling ceramide synthesis
and metabolism hold enormous promise
in the treatment of a broad spectrum of
metabolic disorders.5 Elsevier Inc.REFERENCES
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